onlyTrustedInfo.comonlyTrustedInfo.comonlyTrustedInfo.com
Notification
Font ResizerAa
  • News
  • Finance
  • Sports
  • Life
  • Entertainment
  • Tech
Reading: Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?
Share
onlyTrustedInfo.comonlyTrustedInfo.com
Font ResizerAa
  • News
  • Finance
  • Sports
  • Life
  • Entertainment
  • Tech
Search
  • News
  • Finance
  • Sports
  • Life
  • Entertainment
  • Tech
  • Advertise
  • Advertise
© 2025 OnlyTrustedInfo.com . All Rights Reserved.
Finance

Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?

Last updated: May 5, 2025 8:00 pm
Oliver James
Share
5 Min Read
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?
SHARE

On Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported lower-than-expected first-quarter 2025 earnings.

Vertex reported first-quarter adjusted earnings per share of $4.06, down from $4.76 a year ago, missing the consensus of $4.32.

The cystic fibrosis-focused company reported sales of $2.77 billion, missing the consensus of $2.85 billion.

Total revenue increased by 3%, primarily driven by the continued performance of Trikafta/Kaftrio and an early contribution from the U.S. launch of Alyftrek.

  • In the U.S., total revenue increased 9% to $1.66 billion due to continued strong patient demand and higher net realized pricing.

  • Outside the U.S., total revenue decreased 5% to $1.11 billion, as strong patient demand in established and newer markets was offset by the expected revenue decline in Russia, where Vertex is experiencing a violation of its intellectual property rights.

Also Read: Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data

“Vertex delivered a strong start to 2025 with notable execution across the business as we grow and diversify the revenue base, progress multiple launches and advance the R&D pipeline. We continued to expand our leadership in CF and build global momentum for CASGEVY, and we launched JOURNAVX in moderate-to-severe acute pain,” said Reshma Kewalramani, CEO and President of Vertex. “With multiple programs in pivotal development including povetacicept, which continues to make rapid progress in achieving its potential as a pipeline-in-a-product, and additional programs in early and mid-stage development, Vertex is poised to continue to deliver value for years to come.”

Guidance: Vertex raised the low end of total revenue guidance by $100 million to $11.85 billion-$12 billion from $11.75 billion-$12 billion, compared to the consensus of $11.97 billion.

The guidance also includes an immaterial cost impact from tariffs in 2025 based on currently known tariff rates and regulations.

Vertex has temporarily paused the multiple ascending dose portion of the Phase 1/2 study of VX-522, a nebulized CFTR mRNA therapy, to assess a tolerability issue.

William Blair writes, “While the pause is unfortunate, we believe that the decision to pause the study rather than discontinue it suggests that, beyond the tolerability issue, management is encouraged by the data generated to date given it is open-label.”

Analyst Myles Minter writes, “While there was a slight miss on the top line leading to shares trading off 3% in the aftermarket, management raised the lower end of total revenue guidance, suggesting Street estimates may not have fully encompassed the previously disclosed impacts of an unauthorized Trikafta copy in Russia. We would be buyers on weakness here as the CF franchise still represents one of the most stable long-term growth franchises with a competitive moat in the biotech sector.”

Analyst reactions:

  • Leerink Partners downgrades Vertex from Outperform to Market Perform and lowers the price target from $550 to $503.

  • Needham reiterates Vertex Pharmaceuticals from Hold to Hold.

  • JP Morgan maintains Vertex with an Overweight rating, raising the price target from $512 to $515.

Price Action: VRTX stock closed lower by 9.91% at $450.61 on Tuesday.

Read Next:

  • FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight

Photo via Shutterstock

Latest Ratings for VRTX

Date

Firm

Action

From

To

Feb 2022

RBC Capital

Downgrades

Outperform

Sector Perform

Jan 2022

BMO Capital

Upgrades

Market Perform

Outperform

Dec 2021

Wells Fargo

Initiates Coverage On

Overweight

View More Analyst Ratings for VRTX

View the Latest Analyst Ratings

“ACTIVE INVESTORS’ SECRET WEAPON” Supercharge Your Stock Market Game with the #1 “news & everything else” trading tool: Benzinga Pro – Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

  • VERTEX PHARMACEUTICALS (VRTX): Free Stock Analysis Report

This article Why Did Vertex Pharmaceuticals Stock Fall On Tuesday? originally appeared on Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

You Might Also Like

What Is a Retirement Advisor and Why Do You Need One?

JPMorgan Chase CEO Jamie Dimon Just Delivered Incredible News to Bitcoin Investors

Why Shares of Tempus AI Are Jumping Higher This Week

HELOCs soar back above 8%

Warren Buffett’s succession plan swings into action, but it won’t necessarily be easy for his successor

Share This Article
Facebook X Copy Link Print
Share
Previous Article Kylie Jenner Walks 2025 Met Gala Red Carpet Solo, Attends Without Timothee Chalamet Kylie Jenner Walks 2025 Met Gala Red Carpet Solo, Attends Without Timothee Chalamet
Next Article AP PHOTOS: How bitter wartime enemies France and Germany built a friendship that underpins the EU AP PHOTOS: How bitter wartime enemies France and Germany built a friendship that underpins the EU

Latest News

‘Call Her Alex’ Is an Alex Cooper Infomercial
‘Call Her Alex’ Is an Alex Cooper Infomercial
Entertainment June 9, 2025
Jason Isaacs Champions Tom Felton Playing Draco Malfoy Again, Gives His Blessing to New Lucius Malfoy Actor Johnny Flynn: ‘I Can’t Wait to See What He Comes Up With’
Jason Isaacs Champions Tom Felton Playing Draco Malfoy Again, Gives His Blessing to New Lucius Malfoy Actor Johnny Flynn: ‘I Can’t Wait to See What He Comes Up With’
Entertainment June 9, 2025
‘Doc’ Season 2 Casts Felicity Huffman in Series Regular Role
‘Doc’ Season 2 Casts Felicity Huffman in Series Regular Role
Entertainment June 9, 2025
Christopher Knight Says ‘My Folks Would Not Have Existed Much Longer’ Without His “Brady Bunch ”Paycheck as a Child
Christopher Knight Says ‘My Folks Would Not Have Existed Much Longer’ Without His “Brady Bunch ”Paycheck as a Child
Entertainment June 9, 2025
//
  • About Us
  • Contact US
  • Privacy Policy
onlyTrustedInfo.comonlyTrustedInfo.com
© 2025 OnlyTrustedInfo.com . All Rights Reserved.